Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 1.00 |
| ▸ | MMP3 | P08254 | 12/20 | 1.00 |
| ▸ | MMP9 | P14780 | 5/20 | 1.00 |
| ▸ | MMP14 | P50281 | 5/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | MMP1 | P03956 | 3/20 | 0.87 |
| ▸ | BMP1 | P13497 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435957 | 0.93 | MMP2 (1.00) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7706922 | 0.92 | MMP2 (0.85) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7061522 | 0.91 | MMP2 (0.83) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7709927 | 0.91 | MMP2 (0.83) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL6449143 | 0.91 | MMP2 (0.83) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7109428 | 0.90 | MMP2 (0.82) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7108052 | 0.89 | MMP2 (0.79) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7111094 | 0.88 | MMP2 (0.79) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL7114064 | 0.87 | MMP2 (0.85) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL6436785 | 0.87 | MMP2 (0.85) | MMP2MMP3MMP9MMP14MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20220331389-A1 | SKIN COMPOSITION | EADERM CO., LTD. (JP) | 2022-10-20 | — | — | US | claimed |
| US-11298372-B2 | Composition for ameliorating loss of hair and graying of hair, and use thereof | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2022-04-12 | — | — | US | claimed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | claimed |
| EP-1047665-B1 | MATRIX METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-10-22 | — | — | EP | claimed |
| US-20030099693-A1 | Wafer | PFIZER INC. | 2003-05-29 | — | — | US | claimed |
| WO-2003037395-A1 | WAFER FOR WOUNDS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | claimed |
| US-6350907-B1 | PEPTIDE ENZYME INHIBITORS | PFIZER INC | 2002-02-26 | — | — | US | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20250228875-A1 | METHODS OF TREATING, AMELIORATING AND/OR PREVENTING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AND HETEROTOPIC OSSIFICATION, AND KITS FOR THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-07-17 | — | — | US | disclosed |
| WO-2025076396-A1 | METHODS OF TREATING, AMELIORATING AND/OR PREVENTING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AND HETEROTOPIC OSSIFICATION, AND KITS FOR THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4205750-B1 | NADPH OXIDASE INHIBITOR FOR SUPPRESSING OR IMPROVING HAIR LOSS OR TREATING ALOPECIA | EADERM CO LTD (JP) | 2025-04-09 | — | — | EP | disclosed |
| EP-4499131-A2 | METHODS OF TREATING, AMELIORATING AND/OR PREVENTING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AND HETEROTOPIC OSSIFICATION, AND KITS FOR THE SAME | The Trustees of The University of Pennsylvania (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119365210-A | Methods and kits for treating, ameliorating and/or preventing progressive ossified fibrous tissue dysplasia and ectopic ossification | 宾夕法尼亚大学董事会 | 2025-01-24 | — | — | CN | disclosed |
| US-20140178293-A1 | METHODS FOR IMAGING BONE PRECURSOR CELLS USING DUAL-LABELED IMAGING AGENTS TO DETECT MMP-9 POSITIVE CELLS | BAYLOR COLLEGE OF MEDICINE (US) | 2014-06-26 | — | — | US | disclosed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| EP-1047665-B1 | MATRIX METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-20030099693-A1 | Wafer | PFIZER INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003037395-A1 | WAFER FOR WOUNDS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
| US-6350907-B1 | PEPTIDE ENZYME INHIBITORS | PFIZER INC | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP2 19/4885MMP3 28/4885MMP9 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.